Join
Live feed
·
PRReleasevia Quantisnow
Achieve Life Sciences Inc. logo

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

ByQuantisnow·Wall Street's wire, on your screen.
ACHV· Achieve Life Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACHV (Achieve Life Sciences Inc.) and more on Quantisnow.

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline | Quantisnow